Amylin
1 paper
- Human trial1
Funding
2 grants since 2023National Institute of Neurological Disorders and StrokeUS$1.5mNational Institute of Diabetes and Digestive and Kidney DiseasesUS$451.7k
Latest
10 in 12 monthsAmerican Heart Journal
Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)
Trial protocolCardiovascular disease
Diabetes, Metabolic Syndrome and Obesity
Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review
Systematic review of studies in peopleObesity
Preprints.org
Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication Opportunities
Preprint: cohort study of 761 peopleInterventions
Naunyn-Schmiedeberg's Archives of Pharmacology
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials
Meta-analysis of randomised trialsInterventions
Annals of Medicine and Surgery
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Meta-analysis of randomised trialsObesity
ADA Scientific Sessions 2026 Abstract
Petrelintide, a Human Amylin Analog for the Treatment of Obesity: Efficacy and Safety from the Phase 2 Trial, ZUPREME 1
Randomised trial in 485 peopleObesity